Evaluation of the Wnt signaling pathway as a prognostic marker in patients with urosepsis

Abstract

The Wnt signaling pathway has critical roles in dysregulated inflammation during sepsis; however, its impacts on clinical outcomes remain uncertain. This prospective observational study investigated the association between the Wnt pathway and clinical outcomes in patients with urosepsis. The study included 38 patients with urosepsis and 20 healthy individuals. Wnt3a and Wnt5a levels were measured at admission. The primary outcome was the occurrence of major adverse kidney events (MAKE), defined as new renal replacement therapy, stage 3 acute kidney injury, or death. Both Wnt3a and Wnt5a levels were higher in the patient group than in the control (P = 0.001 and P < 0.001, respectively). The primary outcome occurred in 13 (34.2%) subjects. The levels of Wnt5a were higher in subjects with MAKE than in those without MAKE (P = 0.015); however, Wnt3a levels showed no significant difference. Moreover, Wnt5a levels could be a marker to predict the possibility of MAKE (area under the curve 0.74 [0.57–0.92]; P = 0.016). Serum creatinine levels on day 0, day 5, and on discharge day were evaluated. The levels of creatinine on discharge day were higher in patients with high Wnt5a levels, compared to those with low Wnt5a levels (P = 0.030); however, no difference in Wnt5a levels was observed on day 0 and 5. Wnt3a and Wnt5a levels increased in patients with urosepsis. Moreover, evaluation of Wnt5a levels might help to predict the occurrence of MAKE and renal recovery in these patients.